NO DROP-SHIP ORDERING

 

Prefilled Unit-Dose MVASITM (Bevacizumab-awwb) Syringes 

 

First deliveries scheduled for November 2019.

Submit your preorder today!

 

MVASI™ (a biosimilar to Avastin®), which was approved by the FDA in 2017, is now available in the United States. Both compliance and convenience are now possible with Edge Pharma's unit dose MVASI™ Bevacizumab-awwb syringes.

Edge Pharma offers FDA compliant, prefilled ready-to-administer compounded MVASI™ Bevacizumab-awwb syringes for eye injections without the need to drop-ship vials. Simply register for an online ordering account, submit the appropriate licenses, and start ordering.

No Minimum Ordering Requirements for MVASI™ syringes.

 

MVASI™ Bevacizumab-awwb Ophthalmic Injection 

Concentration = 1.25 mg / 0.05 mL
MVASI™ Syringe Volume = 0.13 mL in a silicone-free Norm-Ject syringe

 

MVASI™ Bevacizumab-awwb Syringe Features 

  • Silicone-Free Norm-Ject syringes
  • Meet new FDA requirements for subvisible particle testing
  • No vial drop-shipping required. Simply log in and order.
  • No contracts required and no minimum orders. Order as few as one syringe.
  • Volume discounts and contracted pricing available. Call or email to inquire.
  • Every batch of compounded MVASI™ syringes from Edge Pharma undergoes rigorous sterility, potency, endotoxin, visual inspection, and subvisible particle analysis before release.

 

References

1. According to the American Academy of Ophthalmology:

"Bevacizumab (Avastin) is widely used off-label for treating neovascular ophthalmic diseases. Approval of the biosimilar [MVASI™], which will carry the generic name bevacizumab-awwb, was based on evidence from 2 comparative clinical trials as well as extensive structural and functional characterization."

https://www.aao.org/headline/amgen-s-bevacizumab-biosimilar-gains-approval

2. Specialty Guideline Management -- AVASTIN (bevacizumab), MVASI (bevacizumab-awwb)

"The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy."

Section B.7.b: "Neovascular (wet) age-related macular degeneration (AMD)""

https://provider.carefirst.com/carefirst-resources/provider/pdf/drug/Avastin-Criteria.pdf

3. Clinical Policy: Bevacizumab (Avastin, Mvasi)

"It is the policy of health plans affiliated with Centene Corporation® that Avastin and Mvasi are medically necessary when the following criteria are met."

Section I.C.1.a: "Neovascular (wet) age-related macular degeneration"

https://www.superiorhealthplan.com/content/dam/centene/policies/pharmacy-policies/CP.PHAR.93%20bevacizumab.pdf

4. According to the Blue Cross Blue Shield of Western New York website: "Drug Therapy Guidelines: Bevacizumab (Avastin® [bevacizumab], Mvasi® [bevacizumab-awwb])"

"Coverage of Avastin or Mvasi is also available for the following ophthalmic indications:"

  • "Neovascular (wet) Age-related macular degeneration (AMD)"
  • "Diabetic Macular Edema (DME)"

https://www.bcbswny.com/content/dam/COMMON/non-secure/provider/drug-therapy-guidelines/B-C-D/bevacizumab.pdf

5. UnitedHealthcare Network Bulletin August 2019: Oncology Medication Clinical Coverage

"Policy update Oct. 1, 2019. The policy will be updated to include preferred product coverage criteria for Avastin® (bevacizumab) and Herceptin® (trastuzumab). Preferred product language will be added as follows:"

  • "Use of Mvasi (bevacizumab-awwb) prior to the use of Avastin and other bevacizumab biosimilar products."

https://www.uhcprovider.com/content/dam/provider/docs/public/resources/news/2019/network-bulletin/August-Network-Bulletin-2019.pdf

Register To Order Online 

Please fill the Form below to create an account. Medical, DEA, or hospital pharmacy licenses are required to order prefilled MVASI™ Bevacizumab-awwb syringes.

Create an account to order

Log-In if you have an account